1
|
Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone Marrow Transplant 2021; 57:176-182. [PMID: 34711917 DOI: 10.1038/s41409-021-01506-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 10/04/2021] [Accepted: 10/13/2021] [Indexed: 12/11/2022]
Abstract
Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a real-life vision and optimizing patient and donor selection. We analyzed epidemiological data reported in a 4 year-monocentric prospective registry, which included all patients presented as candidates for autologous (Auto) and/or allogeneic (Allo) HCT. A total of 543 patients were considered for HCT: 252 (42.4%) for Allo and 291 (57.6%) for Auto. A total of 98 (38.9%) patients were excluded from AlloHCT due to basal disease progression more commonly (18.2%). Seventy-six (30.2%) patients had an HLA identical sibling, whereas 147 (58.3%) patients had only Haplo. UD research was performed in 106 (42%) cases, significantly more often in myeloid than lymphoid malignancies (57% vs 28.7%, p < 0.001) but 61.3% were finally canceled, due to donor or disease causes in 72.4%. With respect to Auto candidates, a total of 60 (20.6%) patients were finally excluded; progression was the most common cause (12%). Currently, Haplo is the most frequent donor type. The high cancellation rate of UD research should be revised to optimize further donor algorithms.
Collapse
Affiliation(s)
- R Parody
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain. .,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
| | - I Sánchez-Ortega
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - A Mussetti
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - B Patiño
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - M Arnan
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - H Pomares
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - E González-Barca
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - S Mercadal
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - C Boqué
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - C Maluquer
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - I Carro
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - M Peña
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - V Clapés
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,H. Comarcal d'Alt Penedés, Vilafranca del Penedés, Barcelona, Spain
| | - S Verdesoto
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - G Bustamante
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - A C Oliveira
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Hospital Sant Camil - St. Pere de Ribes, Barcelona, Spain
| | - C Baca
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,H General de Igualada, Barcelona, Spain
| | - E Cabezudo
- EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d'Espí, Barcelona, Spain
| | - C Talarn
- Institut Català d'Oncologia-Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
| | - L Escoda
- Institut Català d'Oncologia-Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
| | - S Ortega
- Banc de Sang i Teixits, Barcelona, Barcelona, Spain
| | - N García
- Banc de Sang i Teixits, Barcelona, Barcelona, Spain
| | | | - Mar Sánchez-Salmerón
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
| | - C Fusté
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - J Villa
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - E Carreras
- REDMO, Fundació Josep Carreras, Barcelona, Spain
| | - E Domingo-Domènech
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| | - A Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.,Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
| |
Collapse
|
2
|
Fernandez-Miranda I, Pedrosa L, Gómez S, González-Rincón J, Espinet B, Climent F, de la Cruz F, Martín-Acosta P, Colomo L, Salar A, García-Cosio M, García-Arroyo F, Llanos M, Yánguas N, Sequero Lopez S, Mercadal S, Navarro B, Mollejo M, Provencio Pulla M, Sánchez-Beato M. 829MO A gene signature to predict risk of transformation in patients with follicular lymphoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Fernandez‐Miranda I, Dominguez M, Pedrosa L, Gomez S, Gonzalez‐Rincon J, Espinet B, Climent F, Cruz FDL, Martin‐Acosta P, Colomo L, Salar A, Garcia‐Cosio M, Garcia‐Arroyo FR, Llanos M, Yanguas N, Sequero S, Mercadal S, Navarro B, Piris MA, Mollejo M, Provencio M, Sanchez‐Beato M. A GENE SIGNATURE TO PREDICT RISK OF TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.16_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- I. Fernandez‐Miranda
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - M. Dominguez
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - L. Pedrosa
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - S. Gomez
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - J. Gonzalez‐Rincon
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - B. Espinet
- Hospital del Mar Pathology Service Barcelona Spain
| | - F. Climent
- Hospital Universitari de Bellvitge‐IDIBELL Pathology Department Bellvitge Spain
| | - F. de la Cruz
- Hospital Universitario Virgen del Rocío Hematology Department Sevilla Spain
| | - P. Martin‐Acosta
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Research Group in Molecular Cancer Pathology Majadahonda Spain
| | - L. Colomo
- Hospital del Mar Pathology Service Barcelona Spain
| | - A. Salar
- Hospital del Mar Hematology Service Barcelona Spain
| | - M. Garcia‐Cosio
- Hospital Universitario Ramón y Cajal Pathology Department Madrid Spain
| | | | - M. Llanos
- Hospital Universitario de Canarias Oncology Department Tenerife Spain
| | - N. Yanguas
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| | - S. Sequero
- Hospital Universitario San Cecilio Oncology Department Granada Spain
| | - S. Mercadal
- Institut Catala d’Oncologia‐IDIBELL Clinic Hematology Department Bellvitge Spain
| | - B. Navarro
- Hospital Universitario Puerta de Hierro Hematology Department Majadahonda Spain
| | - M. A. Piris
- Hospital Fundación Jiménez Díaz Pathology Department Madrid Spain
| | - M. Mollejo
- Complejo Hospitalario de Toledo Pathology Department Toledo Spain
| | - M. Provencio
- Hospital Universitario Puerta de Hierro Oncology Department Majadahonda Spain
| | - M. Sanchez‐Beato
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana Lymphoma Research Group Majadahonda Spain
| |
Collapse
|
4
|
Muntañola A, Magnano L, Mercadal S, Huguet M, Bobillo S, Bastos‐Oreiro M, Jiménez‐Ubieto A, Rovira J, Rivero A, Alcoceba M, Mozas P, Luizaga L, Alonso‐Álvarez S, Rivas‐Delgado A, Giné E, Caballero D, Sancho JM, López‐Guillermo A. OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.27_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Muntañola
- Hospital Universitari Mútua Terrassa Hematology Barcelona Spain
| | - L. Magnano
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - S. Mercadal
- Hospital Duran Reynals ‐ ICO Hospitalet Hematology Barcelona Spain
| | - M. Huguet
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | - S. Bobillo
- Hospital Vall d'Hebron Hematology Barcelona Spain
| | | | | | - J. Rovira
- Hospital Universitari Joan XXIII ‐ ICO Tarragona Hematology Tarragona Spain
| | - A. Rivero
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - M. Alcoceba
- Hospital Universitario de Salamanca Molecular Biology Salamanca Spain
| | - P. Mozas
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - L. Luizaga
- Hospital Universitari Mútua Terrassa, Pathology Barcelona Spain
| | | | | | - E. Giné
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - D. Caballero
- Complejo Asistencial Universitario de Salamanca /IBSAL Hematology Salamanca Spain
| | - J. M. Sancho
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | | |
Collapse
|
5
|
Velasco R, Mercadal S, Vidal N, Alañá M, Barceló MI, Ibáñez-Juliá MJ, Bobillo S, Caldú Agud R, García Molina E, Martínez P, Cacabelos P, Muntañola A, García-Catalán G, Sancho JM, Camro I, Lado T, Erro ME, Gómez-Vicente L, Salar A, Caballero AC, Solé-Rodríguez M, Gállego Pérez-Larraya J, Huertas N, Estela J, Barón M, Barbero-Bordallo N, Encuentra M, Dlouhy I, Bruna J, Graus F. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 2020; 148:545-554. [PMID: 32524392 DOI: 10.1007/s11060-020-03547-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 05/26/2020] [Indexed: 12/12/2022]
Abstract
INTRODUCTION To assess the management of immunocompetent patients with primary central nervous system lymphomas (PCNSL) in Spain. METHODS Retrospective analysis of 327 immunocompetent patients with histologically confirmed PCNSL diagnosed between 2005 and 2014 in 27 Spanish hospitals. RESULTS Median age was 64 years (range: 19-84; 33% ≥ 70 years), 54% were men, and 59% had a performance status (PS) ≥ 2 at diagnosis. Median delay to diagnosis was 47 days (IQR 24-81). Diagnostic delay > 47 days was associated with PS ≥ 2 (OR 1.99; 95% CI 1.13-3.50; p = 0.016) and treatment with corticosteroids (OR 2.47; 95% CI 1.14-5.40; p = 0.023), and it did not improve over the years. Patients treated with corticosteroids (62%) had a higher risk of additional biopsies (11.7% vs 4.0%, p = 0.04) but corticosteroids withdrawal before surgery did not reduce this risk and increased the diagnostic delay (64 vs 40 days, p = 0.04). Median overall survival (OS) was 8.9 months [95% CI 5.9-11.7] for the whole series, including 52 (16%) patients that were not treated, and 14.1 months (95%CI 7.7-20.5) for the 240 (73.4%) patients that received high-dose methotrexate (HD-MTX)-based chemotherapy. Median OS was shorter in patients ≥ 70 years (4.1 vs. 13.4 months; p < 0.0001). Multivariate analysis identified age ≥ 65 years, PS ≥ 2, no treatment, and cognitive/psychiatric symptoms at diagnosis as independent predictors of short survival. CONCLUSIONS Corticosteroids withdrawal before surgery does not decrease the risk of a negative biopsy but delays diagnosis. In this community-based study, only 73.4% of patients could receive HD-MTX-based chemotherapy and OS remains poor, particularly in elderly patients ≥ 70 years.
Collapse
Affiliation(s)
- R Velasco
- Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. .,Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain. .,Department of Neurology, Neuro-Oncology Unit, Hospital Universitari de Bellvitge and ICO L'Hospitalet, C/Feixa Llarga S/N, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
| | - S Mercadal
- Department of Hematology, Catalan Institute of Oncology-Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - N Vidal
- Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Pathology, Unit of Neuro-Oncology. Hospital Universitari de Bellvitge-ICO Duran i Reynals, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Alañá
- Department of Neurology, Complejo Asistencial Universitario, Salamanca, Spain
| | - M I Barceló
- Department of Neurology, Hospital Universitario Son Espases, Palma de Mallorca, Spain
| | - M J Ibáñez-Juliá
- Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - S Bobillo
- Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
| | - R Caldú Agud
- Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - E García Molina
- Department of Neurology, Virgen de la Arrixaca University Hospital, Murcia, Spain
| | - P Martínez
- Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Cacabelos
- Department of Neurology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, Spain
| | - A Muntañola
- Department of Hematology, Hospital Universitario Mutua de Terrassa, Terrassa, Spain
| | - G García-Catalán
- Department of Neurosurgery, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - J M Sancho
- Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain
| | - I Camro
- Department of Neurology, Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain
| | - T Lado
- Department of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - M E Erro
- Neurology Department, Complejo Hospitalario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - L Gómez-Vicente
- Department of Neurology, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Madrid, Spain
| | - A Salar
- Department of Hematology, Hospital del Mar, Barcelona, Spain
| | - A C Caballero
- Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Solé-Rodríguez
- Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J Gállego Pérez-Larraya
- Departament of Neurology, Clínica Universidad de Navarra, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
| | - N Huertas
- Department of Neurology, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
| | - J Estela
- Department of Neurology, Hospital Parc Taulí, Sabadell, Spain
| | - M Barón
- Unit of Neurology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - N Barbero-Bordallo
- Department of Neurology, Hospital Universitario Rey Juan Carlos, HURJC-HUIE-HCV, Madrid, Spain
| | - M Encuentra
- Department of Hematology, Catalan Institute of Oncology-Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - I Dlouhy
- Department of Hematology and Neurology, Hospital Clínic de Barcelona, Barcelona, Spain
| | - J Bruna
- Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain
| | - F Graus
- Department of Hematology and Neurology, Hospital Clínic de Barcelona, Barcelona, Spain
| | | |
Collapse
|
6
|
Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol 2018; 11:96. [PMID: 30041662 PMCID: PMC6057006 DOI: 10.1186/s13045-018-0639-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 07/09/2018] [Indexed: 01/14/2023] Open
Abstract
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- E Genescà
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. .,ALL Research Group, Josep Carreras Leukaemia Research Institute (IJC), Camí de les Escoles s/n. Edifici IJC, 08916, Badalona, Spain.
| | - A Lazarenkov
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - M Morgades
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - G Berbis
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - N Ruíz-Xivillé
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Gómez-Marzo
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Ribera
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - A González-Pérez
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
| | - S Mercadal
- Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del LLobregat, Barcelona, Spain
| | - R Guardia
- Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona, Spain
| | - M T Artola
- Clinical Hematology Service, Hospital Universitario de Donostia, Donostia, Spain
| | - M J Moreno
- Clinical Hematology Service, Hospital Vírgen de la Victoria, Málaga, Spain
| | - J Martínez-López
- Hematology Department, Hospital 12 de Octubre, CNIO, Universidad Complutense, Madrid, Spain
| | - L Zamora
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Barba
- Clinical Hematology Service, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain
| | - C Gil
- Clinical Hematology Service, Hospital General de Alicante, Alicante, Spain
| | - M Tormo
- Clinical Hematology Service, Hospital Clínico de Valencia, Valencia, Spain
| | - A Cladera
- Clinical Hematology Service, Hospital Son Llàtzer, Palma, Spain
| | - A Novo
- Clinical Hematology Service, Hospital Son Espases, Palma, Spain
| | - M Pratcorona
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Nomdedeu
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J González-Campos
- Clinical Hematology Service, Hospital Vírgen del Rocío, Sevilla, Spain
| | - M Almeida
- Banco Nacional de ADN Carlos III, Universidad de Salamanca, Salamanca, Spain
| | - J Cervera
- Biobanco de la Fe, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain
| | - P Montesinos
- Clinical Hematology Service, Hospital La Fe, Valencia, Spain
| | - M Batlle
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - S Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - J Esteve
- Clinical Hematology Service, Hospital Clínic de Barcelona, Barcelona, Spain
| | - E Feliu
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - F Solé
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - A Orfao
- Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) (CIC), Hospital Clínico Universitario de Salamanca (HUS), Instituto Bio-Sanitario de Salamanca (IBSAL), CIBERONC, Salamanca, Spain
| | - J M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
7
|
Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia 2017; 32:675-684. [PMID: 28804123 PMCID: PMC5843901 DOI: 10.1038/leu.2017.251] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 07/24/2017] [Accepted: 07/27/2017] [Indexed: 02/08/2023]
Abstract
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.
Collapse
Affiliation(s)
- K Karube
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,Department of Pathology and Cell Biology, Graduate School of Medicine and Faculty of Medicine, University of the Ryukyus, Nishihara, Japan
| | - A Enjuanes
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - I Dlouhy
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - P Jares
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - D Martin-Garcia
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - F Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | | | - J Rovira
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - G Clot
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - C Royo
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - A Navarro
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - B Gonzalez-Farre
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - A Vaghefi
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - G Castellano
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - C Rubio-Perez
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - D Tamborero
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - J Briones
- Servei de Patologia, Hospital de Sant Pau, Barcelona, Spain
| | - A Salar
- Department of Pathology, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
| | - J M Sancho
- ICO-Hospital Germans Trias i Pujol, Barcelona, Spain
| | - S Mercadal
- ICO-Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain
| | | | - L Escoda
- Department of Hematology, Hospital Universitari Joan XXIII, Tarragona, Spain
| | - H Miyoshi
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - K Ohshima
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - K Miyawaki
- Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan
| | - K Kato
- Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan
| | - K Akashi
- Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan
| | - A Mozos
- Servei de Patologia, Hospital de Sant Pau, Barcelona, Spain
| | - L Colomo
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,Department of Pathology, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
| | - M Alcoceba
- CIBERONC, Madrid, Spain.,Unidad de Biología Molecular/Histocompatibilidad, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain
| | - A Valera
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - A Carrió
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - D Costa
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - N Lopez-Bigas
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - R Schmitz
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - L M Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - I Salaverria
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - A López-Guillermo
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| | - E Campo
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.,CIBERONC, Madrid, Spain
| |
Collapse
|
8
|
Gonzalez-Barca E, Carrillo E, Grande C, Martín A, Montes-Moreno S, Coronado M, Mercadal S, Roncero J, Perez De Oteyza J, Nicolas C, Rodriguez-Salazar M, Sancho J, Palomera L, Lopez J, Albo C, Peñalver F, Hernandez J, Lopez-Guillermo A, Ramirez M, Jarque I, Bargay J, Canales M, Conde E, Caballero D. PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH-RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_49] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- E. Gonzalez-Barca
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - E. Carrillo
- Hematology; H. Virgen Del Rocio; Sevilla Spain
| | - C. Grande
- Hematology, H. 12 De Octubre; Madrid Spain
| | - A. Martín
- Hematology; Complejo Hospitalario De Salamanca; Salamanca Spain
| | | | - M. Coronado
- Nuclear Medicine, H. U. La Paz; Madrid Spain
| | - S. Mercadal
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - J.M. Roncero
- Hematology; ICO Girona (H.U. Dr. Josep Trueta); Girona Spain
| | | | - C. Nicolas
- Hematology; H. U. Central De Asturias; Oviedo Spain
| | | | - J.M. Sancho
- Hematology; Ico Badalona (H. Germans Trias I Pujol); Barcelona Spain
| | - L. Palomera
- Hematology, H. C. U. Lozano Blesa; Zaragoza Spain
| | - J. Lopez
- Hematology, H. U. Ramón Y Cajal; Madrid Spain
| | - C. Albo
- Hematology, C.H.U De Vigo; Pontevedra Spain
| | | | | | | | - M.J. Ramirez
- Hematology, H. De Jerez, Jerez De La Frontera; Spain
| | - I. Jarque
- Hematology, H. U. Politècnic La Fe; Valencia Spain
| | - J. Bargay
- Hematology, H. Son Llàtzer; Palma Spain
| | | | - E. Conde
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| | - D. Caballero
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| |
Collapse
|
9
|
Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Andrade-Campos M, Rodriguez G, Sancho J, Mercadal S, Salar A, Arranz R, Terol M, Jiménez-Ubieto A, González de Villambrosía S, Bello J, López L, Novelli S, De Cabo E, Infante M, Pardal E, Canals M, González M, Martín A, Caballero M, López-Guillermo A. PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_90] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- L. Magnano
- Hematology; Hospital Clinico de Barcelona; Barcelona Spain
| | | | - M. Alcoceba
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | | | - A. Muntañola
- Hematology; Hospital Universitario Mútua de Terrassa, Terrassa; Barcelona Spain
| | | | - G. Rodriguez
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - J. Sancho
- Hematology; Hospital H. Germans Trias i Pujol (ICO-IJC); Badalona Spain
| | - S. Mercadal
- Hematology; Hospital Duran i Reynals (ICO), Hospitalet de Llobregat; Barcelona Spain
| | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - R. Arranz
- Hematology; Hospital de la Princesa; Madrid Spain
| | - M. Terol
- Hematology; Hospital Clínico de Valencia; Valencia Spain
| | | | | | - J. Bello
- Hematology; Hospital de Nuestra Señora de la Esperanza; Santiago de Compostela Spain
| | - L. López
- Hematology; Hospital MD Anderson; Madrid Spain
| | - S. Novelli
- Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - E. De Cabo
- Hematology; Hospital del Bierzo, Ponferrada; León Spain
| | - M. Infante
- Hematology; Hospital Infanta Leonor; Madrid Spain
| | - E. Pardal
- Hematology; Hospital Virgen del Puerto, Plasencia; Cáceres Spain
| | - M. Canals
- Hematology; Hospital Universitario La Paz; Madrid Spain
| | - M. González
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - A. Martín
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Caballero
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | | |
Collapse
|
10
|
Jiménez Ubieto A, Grande C, Caballero D, Yañez L, Novelli S, Hernández-Garcia M, Manzanares M, Arranz R, Ferreiro J, Bobillo S, Mercadal S, Galego A, López-Jiménez J, Moraleda J, Vallejo C, Albo C, Pérez-Ceballos E, Marrero C, Magnano L, Palomera L, Jarque I, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta J. AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_85] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - C. Grande
- Hematology; Hospital 12 de Octubre; Madrid Spain
| | - D. Caballero
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Yañez
- Hematology; Hospital Universitario Marqués de Valdecilla; Santander Spain
| | - S. Novelli
- Hematology; Hospital Universitario Sant Pau; Barcelona Spain
| | | | - M. Manzanares
- Hematology; Hospital Universitario de Jerez; Jerez Spain
| | - R. Arranz
- Hematology; Hospital Universitario La Princesa; Madrid Spain
| | - J. Ferreiro
- Hematology; Hospital Universitario Donostia-Aránzazu; San Sebastián Spain
| | - S. Bobillo
- Hematology; Hospital Universitario Vall de Hebrón; Barcelona Barcelona Spain
| | - S. Mercadal
- Hematology; Hospital Universitario de Bellvitge, l'Hospitalet de Llobregat; Spain
| | - A. Galego
- Hematology; Hospital Universitario A Coruña, A Coruña; Spain
| | - J. López-Jiménez
- Hematology; Hospital Universitario Ramón y Cajal, Madrid; Madrid Spain
| | - J. Moraleda
- Hematology; Hospital Universitario Virgen de la Arriaxaca, El Palmar; Murcia Spain
| | - C. Vallejo
- Hematology; Hospital Central de Asturias, Asturias; Oviedo Spain
| | - C. Albo
- Hematology; Hospital Universitario de Vigo; Vigo Spain
| | - E. Pérez-Ceballos
- Hematology; Hospital Universitario Morales de Messeguer; Murcia Spain
| | - C. Marrero
- Hematology; Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Santa Cruz de Tenerife; Spain
| | - L. Magnano
- Hematology; Hospital Clinic de Barcelona; Barcelona Spain
| | - L. Palomera
- Hematology; Hospital Clínico Universitario Lozano Blesa; Zaragoza Spain
| | - I. Jarque
- Hematology; Hospital Universitario La Fe; València Spain
| | - A. Martín
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - E. Coria
- Hematology; Hospital Clínico San Carlos; Madrid Spain
| | | | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - J. Lahuerta
- Hematology; Hospital 12 de Octubre; Madrid Spain
| |
Collapse
|
11
|
Salas Q, Climent F, Tapia G, Riasol M, Mercadal S, Domingo Domenech E, Oliveira A, Moreno-Velázquez M, Garcia O, Aguilera C, Fernandez de Sevilla A, Sureda A, Sancho J, González Barca E. CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Q. Salas
- Department of Hematology; Institut Català d'Oncologia Hospitalet; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - G. Tapia
- Pathology Department; Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - M. Riasol
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - S. Mercadal
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - E. Domingo Domenech
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Oliveira
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - M. Moreno-Velázquez
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - O. Garcia
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - C. Aguilera
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Fernandez de Sevilla
- Hematology Department and Department of Clinical Sciences; Institut Català d'Oncologia Hospitalet, IDIBELL, and University of Barcelona; L'Hospitalet de Llobregat, Barcelona Spain
| | - A. Sureda
- Department of Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; L'Hospitalet de Llobregat, Barcelona Spain
| | - J. Sancho
- Hematology Department; ICO-IJC Hospital Germans Trías i Pujol; Badalona, Barcelona Spain
| | - E. González Barca
- Hematology Department and Department of Clinical Sciences; Institut Català d'Oncologia Hospitalet, IDIBELL, and University of Barcelona; L'Hospitalet de Llobregat, Barcelona Spain
| |
Collapse
|
12
|
Mercadal S, Vidal N, López-Parra M, Ibañez M, Caldú R, Bobillo S, Barceló I, García E, Martinez P, Cacabelos P, Dlouhy I, Sancho J, Muntañola A, Gómez L, Erro E, Gállego J, Salar A, Caballero A, Solé M, Huertas N, Estela J, Baron M, Barbero N, González-Barca E, Graus F, Velasco R. Initial management of primary central nervous system lymphoma in Spain in the last decade. The experience of the GELTAMO and Spanish neuro-oncology groups. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Mercadal
- Hematology; Catalan Institute of Oncology. Hospital Duran i Reynals., L'Hospitalet de Llobregat; Barcelona Spain
| | - N. Vidal
- Pathology; Hospital de Bellvitge, L'Hospitalet de Llobregat; Barcelona Spain
| | - M. López-Parra
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Ibañez
- Neurology; Hospital Universitario i Politècnic La Fe; Valencia Spain
| | - R. Caldú
- Neurology; Hospital Universitario Miguel Servet; Zaragoza Spain
| | - S. Bobillo
- Hematology; Hospital Vall d'Hebrón; Barcelona Spain
| | - I. Barceló
- Neurology; Hospital Universitario Son Espases; Palma de Mallorca Spain
| | - E. García
- Neurology; Hospital Universitario Virgen de la Arrixaca; Murcia Spain
| | - P. Martinez
- Hematology; Hospital Universitario Doce de Octubre; Madrid Spain
| | - P. Cacabelos
- Neurology; Complejo hospitalario Santiago Compostela; Santiago Compostela Spain
| | - I. Dlouhy
- Hematology; Hospital Clínic; Barcelona Spain
| | - J. Sancho
- Hematology; ICO. Hospital Germans Trias i Pujol; Badalona Spain
| | - A. Muntañola
- Hematology; Hospital Mutua de Terrassa; Terrassa Spain
| | - L. Gómez
- Neurology; Hospital Quirón; Madrid Spain
| | - E. Erro
- Neurology; Hospital de Navarra; Pamplona Spain
| | - J. Gállego
- Neurology; Clínica Universitaria de Navarra; Pamplona Spain
| | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - A. Caballero
- Hematology; Hospital de Sant Pau; Barcelona Spain
| | - M. Solé
- Hematology; Hospital Virgen del Rocío; Sevilla Spain
| | - N. Huertas
- Neurology; Hospiatl Severo Ochoa; Leganés Spain
| | - J. Estela
- Neurology; Hospital Parc Taulí; Sabadell Spain
| | - M. Baron
- Neurology; Hospital Fundación Alcorcón; Alcorcón Spain
| | - N. Barbero
- Neurology; Hospital Rey Juan Carlos; Móstoles Spain
| | - E. González-Barca
- Hematology; Catalan Institute of Oncology. Hospital Duran i Reynals., L'Hospitalet de Llobregat; Barcelona Spain
| | - F. Graus
- Hematology; Hospital Clínic; Barcelona Spain
| | - R. Velasco
- Neurology; Hospital de Bellvitge, L'Hospitalet de Llobregat; Barcelona Spain
| |
Collapse
|
13
|
Alcoceba M, Magnano L, Alonso-Álvarez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho J, Moreno M, Mercadal S, García-Pallarols F, Cannata J, Teruel A, Rodríguez A, González de Villambrosía S, Bello J, López L, Monsalvo S, Novelli S, de Cabo E, Infante M, Pardal E, Muntañola A, González M, Caballero M, Martín A, López-Guillermo A. CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Alcoceba
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - L. Magnano
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - S. Alonso-Álvarez
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - M. Andrade-Campos
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - N. Espinosa-Lara
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - G. Rodríguez
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - J.M. Sancho
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - M. Moreno
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - S. Mercadal
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - F. García-Pallarols
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - J. Cannata
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - A.I. Teruel
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - A. Rodríguez
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | | | - J. Bello
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - L.I. López
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - S. Monsalvo
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - S. Novelli
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - E. de Cabo
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - M.S. Infante
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - E. Pardal
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - A. Muntañola
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - M. González
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - M.D. Caballero
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - A. Martín
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| | - A. López-Guillermo
- Hematology; Spanish Group of Lymphomas and Autologous Stem-cell Transplantation (GELTAMO); Spain
| |
Collapse
|
14
|
Dlouhy I, Karube K, Enjuanes A, Salaverría I, Pérez-Galán P, Jares P, Martín-García D, Nadeu F, Rivas-Delgado A, Rovira J, Gonzalez B, Mozos A, Clot G, Sancho J, Salar A, Mercadal S, Escola L, Briones J, Colomo L, Alcoceba M, Valera A, Campo E, López-Guillermo A. GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- I. Dlouhy
- Hematology; Hospital Clinic Barcelona; Barcelona Spain
| | - K. Karube
- Department of Pathology and Cell Biology, Graduate School of Medicine and Faculty of Medicine; University of the Ryukyus; Nishihara Japan
| | - A. Enjuanes
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - I. Salaverría
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - P. Pérez-Galán
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - P. Jares
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - D. Martín-García
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - F. Nadeu
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | | | - J. Rovira
- Hematology; Hospital Clinic Barcelona; Barcelona Spain
| | - B. Gonzalez
- Pathology; Hospital Clinic Barcelona; Barcelona Spain
| | - A. Mozos
- Pathology; Hospital Clinic Barcelona; Barcelona Spain
| | - G. Clot
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - J.M. Sancho
- Hematology; ICO-Hospital Germans Trias i Pujol; Barcelona Spain
| | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - S. Mercadal
- Hematology; ICO-Hospital Duran i Reynals; Barcelona Spain
| | - L. Escola
- Hematology; Hospital Universitari Joan XXIII; Tarragona Spain
| | - J. Briones
- Hematology; Hospital de Sant Pau; Barcelona Spain
| | - L. Colomo
- Pathology; Hospital del Mar; Barcelona Spain
| | - M. Alcoceba
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - A. Valera
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - E. Campo
- Hematology; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | | |
Collapse
|
15
|
Andrade Campos M, Mercadal S, Domingo Domenech E, Paredes V, Aguilera C, Oliveira A, de la Banda E, Climent F, Parody R, Fernandez de Sevilla A, Sureda A, Gonzalez Barca E. Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Andrade Campos
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL, CIBERER, ISCIII; Barcelona Spain
| | - S. Mercadal
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. Domingo Domenech
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - V. Paredes
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - C. Aguilera
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - A. Oliveira
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. de la Banda
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL; Barcelona Spain
| | - R. Parody
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - A. Fernandez de Sevilla
- Hematology, Department Clinical Sciences, Institut Català d'Oncologia Hospitalet, IDIBELL.; University of Barcelona; Barcelona Spain
| | - A. Sureda
- Hematology; Institut Català d'Oncologia Hospitalet, IDIBELL; Barcelona Spain
| | - E. Gonzalez Barca
- Hematology, Department Clinical Sciences, Institut Català d'Oncologia Hospitalet, IDIBELL.; University of Barcelona; Barcelona Spain
| |
Collapse
|
16
|
Salas Q, Domingo Domenech E, Mercadal S, Oliveira A, Aguilera C, De la Banda E, Climent F, Lucas A, Garcia N, Baca C, Fernandez de Sevilla A, Sureda A, González Barca E. Effective treatments are required for patients with diffuse large B-cell lymphoma (DLBCL) with primary refractory disease. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_92] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Q.Q. Salas
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. Domingo Domenech
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - S. Mercadal
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - A. Oliveira
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - C. Aguilera
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. De la Banda
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del LLobregat; Barcelona Spain
| | - F. Climent
- Pathology Department; Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del LLobregat; Barcelona Spain
| | - A. Lucas
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - N. Garcia
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - C. Baca
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - A. Fernandez de Sevilla
- Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain. IDIBELL. Departament of Clinical Sciences; University of Barcelona, Hospitalet del LLobregat; Barcelona Spain
| | - A. Sureda
- Hematology Department; Institut Català d'Oncologia Hospitalet, Hospitalet del LLobregat; Barcelona Spain
| | - E. González Barca
- Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain. IDIBELL. Departament of Clinical Sciences; University of Barcelona, Hospitalet del LLobregat; Barcelona Spain
| |
Collapse
|
17
|
García-Noblejas A, Cannata-Ortiz J, Conde E, González Barca E, Gutiérrez N, Rojas R, Vidal MJ, Ramírez MJ, Jiménez-Ubieto A, García-Ruiz JC, Sancho JM, López A, Ríos Rull P, Novelli S, Albo C, Debén G, López-Guillermo A, Nicolás C, González de Villambrosia S, Mercadal S, Martín García-Sancho A, Arranz R. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). Ann Hematol 2017; 96:1323-1330. [PMID: 28536895 DOI: 10.1007/s00277-017-2998-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 04/10/2017] [Indexed: 01/21/2023]
Abstract
Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p < 0.001) and OS (92 vs 16 months, p < 0.001) than the remaining. In univariate analysis, first CR at transplant (p = 0.01) and prior rituximab (p = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant (p = 0.03 and p < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.
Collapse
Affiliation(s)
- A García-Noblejas
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain
| | - J Cannata-Ortiz
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain
| | - E Conde
- HU Marqués de Valdecilla, Santander, Spain
| | | | | | - R Rojas
- HU Reina Sofía, Córdoba, Spain
| | | | | | | | | | - J M Sancho
- H. Germans Trias i Pujol, Barcelona, Spain
| | - A López
- HU Vall d'Hebron, Barcelona, Spain
| | - P Ríos Rull
- HU Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
| | | | - C Albo
- H Xeral-Cíes, Madrid, Spain
| | | | | | - C Nicolás
- HU Central de Asturias, Oviedo, Spain
| | | | - S Mercadal
- Instituto Catalán de Oncología, Barcelona, Spain
| | | | - R Arranz
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain.
| |
Collapse
|
18
|
Velasco R, Mercadal S, Vidal N, Bruna J, González-Barca E, López-Guillermo A, Graus F. OS08.9 Management of Primary Central Nervous System Lymphoma in Spain in the last decade: a case series of the Spanish Group of Neuro-Oncology and GELTAMO. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Velasco R, Mercadal S, Vidal N, López-Guillermo A, Bruna J, Graus F. P17.02 Diagnostic delay and treatment options of Primary Central Nervous System Lymphoma in the last decade: preliminary results of first 50 patients from two Catalan institutions. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Mercadal S, Climent F, Domingo-Doménech E, Oliveira A, Romagosa V, de Sevilla AF, González-Barca E. Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. Clin Med Insights Blood Disord 2013; 6:23-7. [PMID: 25512717 PMCID: PMC4222304 DOI: 10.4137/cmbd.s12713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Diffuse large b-cell lymphoma (DLBCL) is an aggressive and potentially curable lymphoma that presents itself as stage I–II in 30% of all cases. It is known that in these localized stages, 15–20% of patients treated without rituximab eventually relapse, but less data exist regarding rituximab era. We have analyzed clinico-pathological features and risk of relapse in 98 patients with I–II stage DLBCL in complete response (CR) or unconfirmed CR (CRu) after first-line treatment consisting of immunochemotherapy. Twelve patients (12.2%) eventually relapsed. Late relapse, more than two years after diagnosis, occurred in three patients, and early relapse, less than two years after diagnosis, was documented in nine patients. Median time from diagnosis to relapse was 0.61 years for patients with early relapse and 3.66 years for patients with late relapse. The second CR rate obtained was similar in the late and in early relapsing patients, being 33% versus 44% (p = 0.072), respectively. Three-year overall survival (OS) was 22% for early relapsing patients and 33% for late relapsing patients (p = 0.65). In conclusion, patients who are diagnosed with stage I-II DLBCL and achieve a CR/CRu with first line immunochemotherapy have a good prognosis. However, a proportion of patients relapse, and this is less frequent in patients treated with first line with immunochemotherapy. These patients have a poor prognosis.
Collapse
Affiliation(s)
- S Mercadal
- Department of Hematology, L'Hospitalet, Barcelona, Spain
| | - F Climent
- Department of Pathology, L'Hospitalet, Barcelona, Spain
| | | | - A Oliveira
- Department of Hematology, L'Hospitalet, Barcelona, Spain
| | - V Romagosa
- Department of Pathology, L'Hospitalet, Barcelona, Spain
| | | | | |
Collapse
|
21
|
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19:958-63. [PMID: 18303032 DOI: 10.1093/annonc/mdn022] [Citation(s) in RCA: 158] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Mercadal
- Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2007; 19:135-41. [PMID: 17962207 DOI: 10.1093/annonc/mdm447] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Extranodal involvement, including central nervous system (CNS), is a frequent event in patients with mantle cell lymphoma (MCL). However, the incidence, risk factors, and impact on outcome remain controversial. PATIENTS AND METHODS Main clinical, biological, and evolutive features of 82 patients (60 males/22 females; median age: 61 years) diagnosed with MCL (blastoid, 26%) in a single institution were analyzed for risk of CNS involvement and prognosis. RESULTS Most patients had advanced stage and intermediate or high-risk International Prognostic Index (IPI). Eleven patients eventually developed CNS involvement with an actuarial 5-year risk of 26% (95% confidence interval 10% to 42%). In one asymptomatic patient, cerebrospinal fluid infiltration was detected at staging maneuvers (1/62; 1.6%). The remaining 10 patients developed neurological symptoms during the course of the disease (median time from diagnosis, 25 months). Initial variables predicting CNS involvement were blastoid histology, high proliferative index measured by Ki-67 staining, high lactate dehydrogenase (LDH) and intermediate- or high-risk IPI. Histological subtype and serum LDH maintained significance in multivariate analysis. Treatment of CNS infiltration consisted of intrathecal chemotherapy (two cases), and intrathecal chemotherapy plus systemic treatment (seven cases). Median survival after CNS involvement was 4.8 months, patients with this complication having shorter survival than those with no CNS disease. CONCLUSION This study confirms the high incidence of CNS involvement in MCL patients. Treatments aimed at preventing this complication are warranted.
Collapse
Affiliation(s)
- A Ferrer
- Department of Hematology, Hospital Clínic, Postgraduate School of Hematology Farreras Valentí, Institut d'Investigacio Biomedica August Pi i Sunyer, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17:1539-45. [PMID: 16940035 DOI: 10.1093/annonc/mdl162] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Histological transformation (HT) is a well-known event in patients with follicular lymphoma (FL) conferring an unfavorable prognosis. The aim of the study was to analyze incidence and risk factors for HT in a large series of FL patients. PATIENTS AND METHODS 276 patients (median age: 54 years; M139/F137) diagnosed with FL (42% grade 1, 51% 2, 7% 3) in a single institution were studied. Initial treatment consisted of combined chemotherapy in most cases. Median survival was 11.3 years. Main clinic and biological variables were assessed for HT and survival. RESULTS 30 of 276 patients (11%) presented HT after a median follow-up of 6.5 years, with a risk of 15% and 22% at 10 and at 15 years, respectively. All HT corresponded to diffuse large B-cell lymphoma (DLBCL). Grade 3 histology, nodal areas >4, increased LDH and beta(2)-microglobulin, and high-risk IPI and FLIPI were associated with HT. In multivariate analysis, grade 3 histology and FLIPI retained prognostic significance. Only FLIPI predicted HT in grade 1-2 patients. 28 patients received salvage treatment for HT, with a CR rate of 52%. Median survival from transformation was 1.2 years, with 6/13 CR patients being alive >5 years after HT. CONCLUSION FLIPI and histology were the most important variables predicting HT. Upon HT, only patients achieving CR reached prolonged survival, thus emphasizing the need for effective therapies once this event occurs.
Collapse
Affiliation(s)
- E Giné
- Institute of Hematology and Oncology, Department of Hematology and Hematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|